Nonrandom connectivity of the epileptic dentate gyrus predicts a major role for neuronal hubs in seizures

Por Morgan, Robert J., Soltesz, Ivan
Publicado em 2008

Pursuing Paradoxical Proconvulsant Prophylaxis for Epileptogenesis

Por Armstrong, Caren, Morgan, Robert J., Soltesz, Ivan
Publicado em 2009

Double Trouble? Potential for Hyperexcitability Following Both Channelopathic up- and Downregulation of I(h) in Epilepsy

Por Dyhrfjeld-Johnsen, Jonas, Morgan, Robert J., Soltesz, Ivan
Publicado em 2009

Single Application of a CB1 Receptor Antagonist Rapidly Following Head Injury Prevents Long-Term Hyperexcitability in a Rat Model

Por Echegoyen, Julio, Armstrong, Caren, Morgan, Robert J., Soltesz, Ivan
Publicado em 2009

Practical considerations in ovarian cancer chemotherapy

Por Cristea, Mihaela, Han, Ernest, Salmon, Lennie, Morgan, Robert J.
Publicado em 2010

Upregulated H-Current in Hyperexcitable CA1 Dendrites after Febrile Seizures

Por Dyhrfjeld-Johnsen, Jonas, Morgan, Robert J., Földy, Csaba, Soltesz, Ivan
Publicado em 2008

Regulation of Fast-Spiking Basket Cell Synapses by the Chloride Channel ClC–2

Por Földy, Csaba, Lee, Sang-Hun, Morgan, Robert J., Soltesz, Ivan
Publicado em 2010

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study

Por Morgan, Robert J., Leong, Lucille, Chow, Warren, Gandara, David, Frankel, Paul, Garcia, Agustin, Lenz, Heinz-Josef, Doroshow, James H.
Publicado em 2010

Personalized Cancer Genetics Training for Personalized Medicine: Improving community-based health care through a genetically literate workforce

Por Blazer, Kathleen R., MacDonald, Deborah J., Culver, Julie O., Huizenga, Carin R., Morgan, Robert J., Uman, Gwen C., Weitzel, Jeffrey N.
Publicado em 2011

Cytosolic H(2)O(2) mediates hypertrophy, apoptosis, and decreased SERCA activity in mice with chronic hemodynamic overload

Por Qin, Fuzhong, Siwik, Deborah A., Pimentel, David R., Morgan, Robert J., Biolo, Andreia, Tu, Vivian H., Kang, Y. James, Cohen, Richard A., Colucci, Wilson S.
Publicado em 2014

Efficacy and Safety of Bevacizumab Plus Erlotinib for Patients with Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: A Trial of the Chicago, PMH, and California Ph...

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Friberg, Gregory, Kasza, Kristen, Faoro, Leonardo, Salgia, Ravi, Stadler, Walter M., Vokes, Everett E., Fleming, Gini F.
Publicado em 2008

A Phase II Study of Sorafenib in Advanced Uterine Carcinoma / Carcinosarcoma: A Trial of the Chicago, PMH, and California Phase II Consortia

Por Nimeiri, Halla S., Oza, Amit M., Morgan, Robert J., Huo, Dezheng, Elit, Laurie, Knost, James A., Wade, James L., Agamah, Edem, Vokes, Everett E., Fleming, Gini F.
Publicado em 2010

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid, -SAHA) in Metastatic Breast Cancer: A California Cancer Consortium Study

Por Luu, Thehang H, Morgan, Robert J, Leong, Lucille, Lim, Dean, McNamara, Mark, Portnow, Jana, Frankel, Paul, Smith, David D., Doroshow, James H., Gandara, David R, Aparicio, Ana, Somlo, George
Publicado em 2008

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spina...

Por Morgan, Robert J., Synold, Timothy, Mamelak, Adam, Lim, Dean, Al-Kadhimi, Zaid, Twardowski, Przemyslaw, Leong, Lucille, Chow, Warren, Margolin, Kim, Shibata, Stephen, Somlo, George, Yen, Yun, Frankel, Paul, Doroshow, James H.
Publicado em 2010

Pharmcodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients with Advanced Solid Tumors: A California Cancer Consort...

Por Morgan, Robert J., Synold, Timothy W., Longmate, Jeffrey A., Quinn, David I, Gandara, David, Lenz, Heinz-Josef, Ruel, Christopher, Xi, Bixin, Lewis, Michael D., Colevas, A. Dimitrios, Doroshow, James, Newman, Edward M.
Publicado no Cancer Chemother Pharmacol (2015)

A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fuoro-2′-deoxycytidine, administered with tetrahydrouridine

Por Newman, Edward M., Morgan, Robert J., Kummar, Shivaani, Beumer, Jan H., Blanchard, M. Suzette, Ruel, Christopher, El-Khoueiry, Anthony B., Carroll, Mary I., Hou, Jessie M., Li, Chun, Lenz, Heinz J., Eiseman, Julie L., Doroshow, James H.
Publicado no Cancer Chemother Pharmacol (2015)

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Por Shibata, Stephen I., Doroshow, James H., Frankel, Paul, Synold, Timothy W., Yen, Yun, Gandara, David R., Lenz, Heinz-Josef, Chow, Warren A., Leong, Lucille A., Lim, Dean, Margolin, Kim A., Morgan, Robert J., Somlo, George, Newman, Edward M.
Publicado em 2009

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced stage solid cancers – A California C...

Por Chao, Joseph, Synold, Timothy W., Morgan, Robert J., Kunos, Charles, Longmate, Jeff, Lenz, Heinz-Josef, Lim, Dean, Shibata, Stephen, Chung, Vincent, Stoller, Ronald G., Belani, Chandra P., Gandara, David R., McNamara, Mark, Gitlitz, Barbara J., Lau, Derick H., Ramalingam, Suresh S., Davies, Angela, Espinoza-Delgado, Igor, Newman, Edward M., Yen, Yun
Publicado em 2011

NCCN Work Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies

Por Venook, Alan P., Arcila, Maria E., Benson, Al B., Berry, Donald A., Camidge, David Ross, Carlson, Robert W., Choueiri, Toni K., Guild, Valerie, Kalemkerian, Gregory P., Kurzrock, Razelle, Lovly, Christine M., McKee, Amy E., Morgan, Robert J., Olszanski, Anthony J., Redman, Mary W., Stearns, Vered, McClure, Joan, Birkeland, Marian L.
Publicado no J Natl Compr Canc Netw (2014)

Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer

Por Kummar, Shivaani, Oza, Amit M., Fleming, Gini F., Sullivan, Daniel M., Gandara, David R., Naughton, Michael J., Villalona-Calero, Miguel A., Morgan, Robert J., Szabo, Peter M., Youn, Ahrim, Chen, Alice P., Ji, Jiuping, Allen, Deborah E., Lih, Chih-Jian, Mehaffey, Michele G., Walsh, William D., McGregor, Paul M., Steinberg, Seth M., Williams, Paul M., Kinders, Robert J., Conley, Barbara A., Simon, Richard M., Doroshow, James H.
Publicado no Clin Cancer Res (2015)